Directors Report to the

1
Directors Report to the National Advisory
Council on Drug Abuse
May 17, 2005
2
Budget Update
Policy Issues
Recent NIDA Activities Events
3
(No Transcript)
4
NIDA BUDGET
(Thousands)
NonAIDS
AIDS
TOTAL
Increase Over Prior Year
5
(No Transcript)
6
NEW Supplemental Ethics Regulation
That Affects ALL NIH Employees
Sets out broad prohibitions regarding Outside
activities Holdings Awards
Current Status Pending Response From Employees
7
Recent NIDA Activities Events
8
NIDA PAs and RFAs Just Issued

• Collaborative Multisite Research in Addiction
  (COMRAD) (PA-05-067)
• Minority Institutions Drug Abuse Research
  Development Program (MIDARP) (PAR-05-069)
• Drug Abuse Dissertation Research Epidemiology,
• Prevention, Treatment, Services and Women
  and Sex/
• Gender Differences (PAR-05-083)
• Inhalant Abuse Supporting Broad-Based Research
  Approaches (PA-05-099)
• Strategic Program for Innovative Research on Drug
  
• Addiction Pharmacotherapy (SPIRDAP)
  (RFA-DA-05-009)

9
PAs and RFAs Recently Issued With Other NIH
Components/Agencies
13 New PAs and 4 New RFAs
Foci include Neurobiology Co-morbidity HIV/AIDS
Brain Development Research Training Software/Biome
dical Computing International Collaboration
10
NIDA
National Institute on Drug Abuse
Office of the Director
Nora D. Volkow, MD
Director
Director, AIDS Research
HIV/AIDS Research
Special Populations Office
Timothy P. Condon, Ph.D.
Deputy Director
Laura S. Rosenthal
Associate Director for Management
Dr. Jacques Normand Will Provide an Update
Office of Extramural Affairs
Office of Planning Resource Management
Office of Science Policy Communications
Center for the Clinical Trials Network
Teresa Levitin, PhD
Laura Rosenthal
Timothy Condon, PhD
Betty Tai, PhD
Division of Clinical Neuroscience, Development
Behavioral Treatment
Division of Epidemiology, Services Prevention
Research
Division of Pharmacotherapies Medical
Consequences of Drug Abuse
Division of Basic Neurosciences Behavior
Research
Intramural Research Program
David Shurtleff, PhD
Frank Vocci, PhD
Wilson Compton, MD, MPE
Barry Hoffer, MD, PhD
Joseph Frascella, PhD
11
NIDA
National Institute on Drug Abuse
Office of the Director
Nora D. Volkow, MD
Special Population/ Health Disparities
Director
Director, AIDS Research
Special Populations Office
Timothy P. Condon, Ph.D.
Deputy Director
Laura S. Rosenthal
Associate Director for Management
Dr. Jose Szapocznik Will Report on Minority
Health Disparities Workgroup Findings
Recommendations
Office of Extramural Affairs
Office of Planning Resource Management
Office of Science Policy Communications
Center for the Clinical Trials Network
Teresa Levitin, PhD
Laura Rosenthal
Timothy Condon, PhD
Betty Tai, PhD
Division of Clinical Neuroscience, Development
Behavioral Treatment
Division of Epidemiology, Services Prevention
Research
Division of Pharmacotherapies Medical
Consequences of Drug Abuse
Division of Basic Neurosciences Behavior
Research
Intramural Research Program
David Shurtleff, PhD
Frank Vocci, PhD
Wilson Compton, MD, MPE
Barry Hoffer, MD, PhD
Joseph Frascella, PhD
12
NIDA
National Institute on Drug Abuse
Office of the Director
Nora D. Volkow, MD
Director
Director, AIDS Research
Special Populations Office
Timothy P. Condon, Ph.D.
Deputy Director
Laura S. Rosenthal
Associate Director for Management
Office of Extramural Affairs
Office of Planning Resource Management
Office of Science Policy Communications
Center for the Clinical Trials Network
CCTN
Teresa Levitin, PhD
Laura Rosenthal
Timothy Condon, PhD
Betty Tai, PhD
Division of Clinical Neuroscience, Development
Behavioral Treatment
Division of Epidemiology, Services Prevention
Research
Division of Pharmacotherapies Medical
Consequences of Drug Abuse
Division of Basic Neurosciences Behavior
Research
Intramural Research Program
David Shurtleff, PhD
Frank Vocci, PhD
Wilson Compton, MD, MPE
Barry Hoffer, MD, PhD
Joseph Frascella, PhD
13
The National Drug Abuse Treatment Clinical Trials
Network (RFA-DA-05-001) Issued July 7, 2004
Application Receipt Date October 14, 2004
15 Applications Received -- 4 New
Applications Reviewed 13 Scored
14
CTN Clinical Coordinating Center Contract Awarded
to The EMMES Corporation
CTN Data and Statistics Center (DSC) Contract
Awarded to Duke Clinical Research Institute (DCRI)
15
Update on New CTN Protocols

• Starting Treatment with Agonist Replacement
• Therapies (START) compare the effect of
• buprenorphine/naloxone and methadone on
• liver function 10 sites, January 2006
• Randomized Controlled Trial of Methylphenidate
• in Adolescents with ADHD and Substance Use
• Disorders 12 sites, Fall 2005
• Methylphenidate in Maintaining Abstinence in
• Smokers with ADHD 6 sites, Fall 2005
• Prescription Opioid Addiction Treatment
• Study (POATS) 12 sites, Fall 2005

16
NIDA
National Institute on Drug Abuse
Office of the Director
Nora D. Volkow, MD
Director
Director, AIDS Research
Special Populations Office
Timothy P. Condon, Ph.D.
Deputy Director
Laura S. Rosenthal
Associate Director for Management
Office of Extramural Affairs
Office of Planning Resource Management
Office of Science Policy Communications
Center for the Clinical Trials Network
Teresa Levitin, PhD
Laura Rosenthal
Timothy Condon, PhD
Betty Tai, PhD
Division of Clinical Neuroscience, Development
Behavioral Treatment
Division of Epidemiology, Services Prevention
Research
Division of Pharmacotherapies Medical
Consequences of Drug Abuse
Division of Basic Neurosciences Behavior
Research
Intramural Research Program
DPMCDA
David Shurtleff, PhD
Frank Vocci, PhD
Wilson Compton, MD, MPE
Barry Hoffer, MD, PhD
Joseph Frascella, PhD
17
REPORT from the Medications Development
Program Work Group 2005 National Institute on
Drug Abuse National Institutes of Health U.S.
Department of Health and Human Services
18
Committee Members
Bankole Johnson, M.D., Ph.D. UT San
Antonio Peter Kalivas, Ph.D. Med U South
Carolina Herb Kleber, M.D. Columbia
University George Koob, Ph.D. Scripps Research
Institute Mary Jeanne Kreek, M.D. Rockefeller
University
Bertha Madras, Ph.D. Harvard Medical
School Eric Nestler, M.D., Ph.D. Southwestern
University Scott Reines, M.D., Ph.D. Johnson
Johnson Ray White, Ph.D. UC San Francisco
Science Writer (Contractor) Jennifer Elcano, M.A.
NIDA Staff Denise Pintello, Ph.D. M.S.W.
19
Summary of Workgroup Recommendations

• Internal Organization
• Create a SAB to advise on internal efficiencies
  decision
• making
• Interactions with other NIDA Divisions
• Restructure relationships, especially with CCTN
  and IRP
• Interactions with Pharmaceutical Companies
• Establish NIDA as an asset to pharma for abuse
  liability
• screening and clinical trials
• Role of Genetics
• Develop a human genetic resource via
  collaborations
• between MDP and CCTN

20
Medications Development Scientific Workgroup
Members
First Meeting Hyatt Regency Hotel Bethesda,
MD March 21-22, 2005
Kenneth Davis, M.D. Lisa H. Gold, Ph.D. Suneel
Gupta, Ph.D. Bankole Johnson, M.D.,
Ph.D. Peter Kalivas, Ph.D. Herb Kleber,
M.D. Thomas R. Kosten, M.D. Susan
Learned-Coughlin, Pharm.D, Ph.D. Bertha Madras,
Ph.D. Eric Nestler, M.D., Ph.D. Charles P.
OBrien, M.D., Ph.D. Kenner Rice, Ph.D.
21
   Interactions With Other NIDA Components

• Starting Treatment with Agonist Replacement
• Therapies (START) Study (with CCTN)
• Institute-wide Workgroup with Representatives
• from CCTN, IRP and all Extramural Divisions

22
NIDA
National Institute on Drug Abuse
Office of the Director
Nora D. Volkow, MD
Director
Director, AIDS Research
Special Populations Office
Timothy P. Condon, Ph.D.
Deputy Director
Laura S. Rosenthal
Associate Director for Management
Office of Extramural Affairs
Office of Planning Resource Management
Office of Science Policy Communications
Center for the Clinical Trials Network
Teresa Levitin, PhD
Laura Rosenthal
Timothy Condon, PhD
Betty Tai, PhD
Division of Clinical Neuroscience, Development
Behavioral Treatment
Division of Epidemiology, Services Prevention
Research
Division of Pharmacotherapies Medical
Consequences of Drug Abuse
Division of Basic Neurosciences Behavior
Research
Intramural Research Program
DBNBR
David Shurtleff, PhD
Frank Vocci, PhD
Wilson Compton, MD, MPE
Barry Hoffer, MD, PhD
Joseph Frascella, PhD
23
NIH IC Directors Roadmap Retreat April 20, 2005

• Molecular Libraries

24
NIH Neuroscience Blueprint
FY 2005 (Tap 0.15)
FY 2006 (Tap 0.30)
Project Team Lead IC GENSAT
expansion NINDS Neurobiology of Disease
Training Supplements NIMH Neuroscience
Inventory NIDA
Project Team Lead IC Core Grants
NINDS Neuromouse NIMH Training NIDA

• Neuroimaging Training
• Computational Neuroscience
• Neurobiology of Disease

25
Neuroscience Blueprint 06 Training Project Team
Laurence Stanford, NIDA, Co-Chair
Susan Weiss, NIDA, Co-Chair
Beth Babecki, NIDA Robert Baughman, NINDS Allison
Chausmer, NIDA Alison Cole, NIGMS Nancy Desmond,
NIMH Gayathri J Dowling, NIDA Dennis Glanzman,
NIMH Lindsey Grandison, NIAAA Steven Grant,
NIDA Kevin Hardwick, NIDCR Deborah Henken,
NICHD Chyren Hunter, NEI Henry Khachaturian,
NIBIB Teresa Levitin, NIDA Yuan Liu, NINDS Susan
Molchan, NIA
Andrew Monjan, NIA Juanita Nelson, NIDA Nancy
Pearson, NCCAM Nancy Pilotte, NIDA Suman Rao
King, NIDA Charles Sharp, NIDA Carol Shreffler,
NIEHS David Shurtleff, NIDA Karen Skinner,
NIDA Roger Sorensen, NIAAA Daniel Sklare,
NIDCD Mark Swieter, NIDA Meredith
Temple-OConnor, NIBIB Susan Volman, NIDA Kenneth
Whang, NSF
26
Training Subgroups

• Neuroimaging
• Neurobiology of Disease
• Computational Neuroscience

27
Interdisciplinary Predoctoral Trainingin
Neuroscience Imaging Integrating First
Principles and Application

• Purpose
• To develop interdisciplinary, predoctoral
  training programs that integrate imaging
  technologies, neuroscience applications, and the
  underlying neurobiological principles with the
  aim of creating a
• cadre of scientists who can optimally utilize
  imaging technologies to address neuroscience
  questions

28
Neurobiology of Disease Training in
Translational Research in Neuroscience
Purpose Train MD, PhD and other scientists in
the multiple theories, techniques, analytic
strategies and objectives of research on the
neurobiology of disease
29
Computational Neuroscience From Model to
Biology and Back Again
Purpose Interdisciplinary training of pre-
and postdoctoral fellows competent in the
theories, principles and application of the
physical, computer, or mathematical sciences
to experimental neuroscience
30
NIDA
National Institute on Drug Abuse
Office of the Director
Nora D. Volkow, MD
Director
Director, AIDS Research
Special Populations Office
Timothy P. Condon, Ph.D.
Deputy Director
Laura S. Rosenthal
Associate Director for Management
Office of Extramural Affairs
Office of Planning Resource Management
Office of Science Policy Communications
Center for the Clinical Trials Network
Teresa Levitin, PhD
Laura Rosenthal
Timothy Condon, PhD
Betty Tai, PhD
Division of Clinical Neuroscience, Development
Behavioral Treatment
Division of Epidemiology, Services Prevention
Research
Division of Pharmacotherapies Medical
Consequences of Drug Abuse
Division of Basic Neurosciences Behavior
Research
Intramural Research Program
DCNDBT
David Shurtleff, PhD
Frank Vocci, PhD
Wilson Compton, MD, MPE
Barry Hoffer, MD, PhD
Joseph Frascella, PhD
31
MRI Study of Normal Brain
Development(N500)

• Create a database of behavioral and brain MRI
  development data for 0-18 years
• Analyze structural-behavioural relationships
• Develop technique for dissemination of results

32
Neurobiology of Behavioral Treatment Recovery
of Brain Structure and Function RFA-DA-05-006
22 Applications Received
Consequences of Drug Abuse Alcohol Exposure on
Brain Behavioral Development RFA-DA-05-007
Issued with NIAAA -- 36 Applications Received
HIV Drug Abuse Interventions Among Pregnant
Women in Drug Abuse Treatment RFA-DA-05-008
16 Applications Received
33
NIDA
National Institute on Drug Abuse
Office of the Director
Nora D. Volkow, MD
Director
Director, AIDS Research
Special Populations Office
Timothy P. Condon, Ph.D.
Deputy Director
Laura S. Rosenthal
Associate Director for Management
Office of Extramural Affairs
Office of Planning Resource Management
Office of Science Policy Communications
Center for the Clinical Trials Network
Teresa Levitin, PhD
Laura Rosenthal
Timothy Condon, PhD
Betty Tai, PhD
Division of Clinical Neuroscience, Development
Behavioral Treatment
Division of Epidemiology, Services Prevention
Research
Division of Pharmacotherapies Medical
Consequences of Drug Abuse
Division of Basic Neurosciences Behavior
Research
Intramural Research Program
DESPR
David Shurtleff, PhD
Frank Vocci, PhD
Wilson Compton, MD, MPE
Barry Hoffer, MD, PhD
Joseph Frascella, PhD
34
Effectively Breaking the Cycle of Drugs and
Crime Research Treatment Provide the
Answers Sponsored by The Friends of
NIDA March 15, 2005
35
CJ-DATS UpdateCriminal Justice Drug Abuse
Treatment Studies

• 6 studies in the field focused on
• Reducing HIV risk behavior
• Screening for mental illness
• Transitioning from prison to community
• 2 juvenile justice studies being developed
• Community re-entry and HIV risk behaviors
• 2 HIV studies being developed
• Men
• Women

www.cjdats.org
36
CASA Primary Care Meeting
37
Screening and Intervention for Youth in Primary
Care Settings RFA-DA-04-006
Issued with SAMHSA, HRSA and AHCPR
Purpose Expand the role of primary care in
addressing problem drug useespecially
marijuanaamong youth in the pre-dependency phase
of drug abuse. 36 applications 7 awards made in
September, 2004 4 Behavioral Treatment
Research 2 Health Services Research 1
Prevention Research
38
Congressional Hearings
Consequences of the Abuse of Anabolic Steroids
Testimony before the Committee on Government
Reform -- March 17, 2005 Fiscal Year 2006 Budget
Request Testimony before the House Subcommittee
on Labor-HHS-Education Approp. -- March 9,
2005 Senate Subcommittee on Labor-HHS-Education
Approp. -- April 6, 2005 Methamphetamine
Abuse Testimony before the Senate Subcommittee on
Labor, HHS, Education, Related Agencies --
Committee on Appropriations -- April 21,
2005 Substance Abuse and Mental Health Research
Services Testimony before the House
Subcommittee on Labor, HHS Education Committee
on Appropriations -- April 27, 2005
39
NIDA Also Co-sponsored or Had Involvement in
CSAT Annual Grantees Meeting on
Adolescent Treatment March 23, 2005
2005 SAMHSA/NIDA Buprenorphine Summit April
11-12, 2005
Impact of Drug Formulation on Abuse
Liability, Safety and Regulatory Decisions
(CPDD) April 19-20, 2005 Methamphetamine
Research Workgroup Meeting March 9-10, 2005
PRIDE 2005 A Special Research Track from
NIDA April 6-9, 2005
40
9th Annual PRISM Awards Event Beverly Hills
Hotel April 28, 2005 Event will air as a
one-hour TV special on FX Network September 4,
2005 at 500pm
41
Cannabis Dependence Treatment Where We Are,
Where We Are Going Issue Workshop Tuesday, May
24, 2005 -- 1100 am to 1230 pm Increases in
Opioid Analgesic Abuse Concerns and
Strategies Symposium Tuesday, May 24, 2005 --
200 pm to 500 pm New Scientific Advances in
the Neurobiology of Behavior Symposium
Wednesday, May 25, 2005 -- 200 pm to 500
pm Neurobiology of Compulsive Reward-Seeking Sym
posium Thursday, May 26, 2005 -- 200 pm to 500
pm
42
NIDA-Sponsored Events at CPDD 2005
A record number of posters from CTN research will
be presented at this years meeting
International Forum (June 17th - 19th) Review
Evaluation of NIDA Targets for Potential NIH
Roadmap Library Screening Efforts  NIDA
Tutorials  Translating Basic Research from
Neural, Behavioral, Social Sciences to
Prevention Proteomics Its Application to Drug
Abuse Mice Tales Novel Insights Into
Understanding Addiction NIDA Training
Mixer NIDA/CPDD Grant-writing Workshop Pharmacog
enetics Drug Abuse Research  
June 17th
June 18th
June 20th
June 21st
June 22nd
43
(No Transcript)
44
Commissioned articles highlighting
current progress in the neurobiology of
feeding regulation, energy metabolism and
obesity Sponsored by the
Obesity Research Task Force of the
National Institutes of Health

• NIDA
• NIDDK
• NIAAA
• NHLBI

45
(No Transcript)